Literature DB >> 29304365

PD-1 inhibition in sarcoma still needs investigation.

Maud Toulmonde1, Antoine Italiano2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29304365     DOI： 10.1016/S1470-2045(17)30921-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  6 in total

1.  PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.

Authors:  H Chen; H Liu; J Ai; X Du; Y Sun; S Xiao
Journal:  Clin Transl Oncol       Date:  2021-11-06       Impact factor: 3.405

2.  Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis.

Authors:  Dionisia Quiroga; David A Liebner; Jennifer S Philippon; Sarah Hoffman; Yubo Tan; James L Chen; Scott Lenobel; Paul E Wakely; Raphael Pollock; Gabriel Tinoco
Journal:  BMC Cancer       Date:  2020-06-05       Impact factor: 4.430

3.  Advances in soft-tissue sarcoma - There are no mistakes, only lessons to learn!

Authors:  Sameer Rastogi; Parisa Manasa; Aditi Aggarwal; Kaushal Kalra
Journal:  South Asian J Cancer       Date:  2019 Oct-Dec

4.  High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies.

Authors:  Maud Toulmonde; Carlo Lucchesi; Stéphanie Verbeke; Amandine Crombe; Julien Adam; Damien Geneste; Vanessa Chaire; Audrey Laroche-Clary; Raul Perret; François Bertucci; Frederic Bertolo; Laurence Bianchini; Bérengère Dadone-Montaudie; Todd Hembrough; Steve Sweet; Yeoun Jin Kim; Fabiola Cecchi; François Le Loarer; Antoine Italiano
Journal:  EBioMedicine       Date:  2020-11-28       Impact factor: 8.143

5.  IDO Targeting in Sarcoma: Biological and Clinical Implications.

Authors:  Imane Nafia; Maud Toulmonde; Doriane Bortolotto; Assia Chaibi; Dominique Bodet; Christophe Rey; Valerie Velasco; Claire B Larmonier; Loïc Cerf; Julien Adam; François Le Loarer; Ariel Savina; Alban Bessede; Antoine Italiano
Journal:  Front Immunol       Date:  2020-03-05       Impact factor: 7.561

Review 6.  Kynurenines as a Novel Target for the Treatment of Malignancies.

Authors:  Adrian Mor; Anna Tankiewicz-Kwedlo; Dariusz Pawlak
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.